Quantitative Ocular Surface Changes in Patients Undergoing Immune Checkpoint Inhibitor Therapy.

Kevin ChenMaria Carolina Ibañez BruronSebastian MondacaGonzalo PizarroPaulina LibermanMeghan K Berkenstock

Published in: Ocular immunology and inflammation (2023)

A significant proportion of patients experience changes in ocular surface markers while treated with ICIs. Medical intervention can lead to stabilization of ocular surface disease.

Keyphrases

patients undergoing
end stage renal disease
newly diagnosed
randomized controlled trial
healthcare
chronic kidney disease
prognostic factors
high resolution
stem cells
mesenchymal stem cells
bone marrow
cell therapy